BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 19648117)

  • 1. Nutlin-3 affects expression and function of retinoblastoma protein: role of retinoblastoma protein in cellular response to nutlin-3.
    Du W; Wu J; Walsh EM; Zhang Y; Chen CY; Xiao ZX
    J Biol Chem; 2009 Sep; 284(39):26315-21. PubMed ID: 19648117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1.
    Ray RM; Bhattacharya S; Johnson LR
    Apoptosis; 2011 Jan; 16(1):35-44. PubMed ID: 20812030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas.
    Künkele A; De Preter K; Heukamp L; Thor T; Pajtler KW; Hartmann W; Mittelbronn M; Grotzer MA; Deubzer HE; Speleman F; Schramm A; Eggert A; Schulte JH
    Neuro Oncol; 2012 Jul; 14(7):859-69. PubMed ID: 22591662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.
    Elison JR; Cobrinik D; Claros N; Abramson DH; Lee TC
    Arch Ophthalmol; 2006 Sep; 124(9):1269-75. PubMed ID: 16966622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MYCN sensitizes neuroblastoma to the MDM2-p53 antagonists Nutlin-3 and MI-63.
    Gamble LD; Kees UR; Tweddle DA; Lunec J
    Oncogene; 2012 Feb; 31(6):752-63. PubMed ID: 21725357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. p53-mediated growth suppression in response to Nutlin-3 in cyclin D1 transformed cells occurs independently of p21.
    Kan CE; Patton JT; Stark GR; Jackson MW
    Cancer Res; 2007 Oct; 67(20):9862-8. PubMed ID: 17942917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma.
    Drakos E; Thomaides A; Medeiros LJ; Li J; Leventaki V; Konopleva M; Andreeff M; Rassidakis GZ
    Clin Cancer Res; 2007 Jun; 13(11):3380-7. PubMed ID: 17545546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Restoration of p53 pathway by nutlin-3 induces cell cycle arrest and apoptosis in human rhabdomyosarcoma cells.
    Miyachi M; Kakazu N; Yagyu S; Katsumi Y; Tsubai-Shimizu S; Kikuchi K; Tsuchiya K; Iehara T; Hosoi H
    Clin Cancer Res; 2009 Jun; 15(12):4077-84. PubMed ID: 19509161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nutlin-3 down-regulates retinoblastoma protein expression and inhibits muscle cell differentiation.
    Walsh EM; Niu M; Bergholz J; Xiao ZX
    Biochem Biophys Res Commun; 2015 May; 461(2):293-9. PubMed ID: 25871794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway.
    Koster R; Timmer-Bosscha H; Bischoff R; Gietema JA; de Jong S
    Cell Death Dis; 2011 Apr; 2(4):e148. PubMed ID: 21509038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 antagonist can inhibit tumor growth in hepatocellular carcinoma with different types of p53 in vitro.
    Wang J; Zheng T; Chen X; Song X; Meng X; Bhatta N; Pan S; Jiang H; Liu L
    J Gastroenterol Hepatol; 2011 Feb; 26(2):371-7. PubMed ID: 21261729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of Hsp90 by 17AAG antagonizes MDMX and synergizes with Nutlin to induce p53-mediated apoptosis in solid tumors.
    Vaseva AV; Yallowitz AR; Marchenko ND; Xu S; Moll UM
    Cell Death Dis; 2011 May; 2(5):e156. PubMed ID: 21562588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficient activation of p53 pathway in A549 cells exposed to L2, a novel compound targeting p53-MDM2 interaction.
    Zhang L; Zhang J; Hu C; Cao J; Zhou X; Hu Y; He Q; Yang B
    Anticancer Drugs; 2009 Jul; 20(6):416-24. PubMed ID: 19579266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276.
    Li R; Zatloukalova P; Muller P; Gil-Mir M; Kote S; Wilkinson S; Kemp AJ; Hernychova L; Wang Y; Ball KL; Tao K; Hupp T; Vojtesek B
    Cell Mol Biol Lett; 2020; 25():41. PubMed ID: 32874188
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The histone demethylase JMJD2B is critical for p53-mediated autophagy and survival in Nutlin-treated cancer cells.
    Duan L; Perez RE; Lai X; Chen L; Maki CG
    J Biol Chem; 2019 Jun; 294(23):9186-9197. PubMed ID: 31036564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells.
    Rigatti MJ; Verma R; Belinsky GS; Rosenberg DW; Giardina C
    Mol Carcinog; 2012 May; 51(5):363-78. PubMed ID: 21557332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.